- Investing.com
Financial Tightrope | luebird bio faces critical cash constraints, with resources projected to last only until Q2 2025, raising concerns about long-term viability and product launch execution |
Gene Therapy Promise | Explore bluebird's innovative treatments for genetic diseases, including Lyfgenia for sickle cell disease, which show potential despite challenging market conditions |
Analyst Outlook | Price targets range from $2 to $40, reflecting diverse views on bluebird's future. Barclays maintains an Overweight rating, while RBC Capital Markets rates it Sector Perform |
Strategic Restructuring | Learn how bluebird's cost-cutting measures aim to achieve cash flow break-even by H2 2025, balancing financial stability with the need for effective product launches |
Metrics to compare | BLUE | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipBLUEPeersSector | |
|---|---|---|---|---|
P/E Ratio | Unlock | NaN | NaN | Unlock |
PEG Ratio | Unlock | NaN | NaN | Unlock |
Price/Book | Unlock | NaN | NaN | Unlock |
Price / LTM Sales | Unlock | NaN | NaN | Unlock |
Upside (Analyst Target) | Unlock | NaN | NaN | Unlock |
Fair Value Upside | Unlock | NaN | NaN | Unlock |